𝔖 Bobbio Scriptorium

✦ LIBER ✦

After 10 years of follow-up, preoperative chemotherapy is still safe in operable breast cancer: Clinical and translational results from the European Organisation for Research and Treatment of Cancer Trial 10902

✍ Scribed by J.G.H. Van Nes; Van der Hage; J. Bogaerts; I. Delmotte; M. De Vos; P. Therasse; J.P. Julien; M. Tubiana-Hulin; C.J.H. Van de Velde

Book ID: 118624648
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 137 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)80369-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved survival after one course of pe

Improved survival after one course of perioperative chemotherapy in early breast cancer patients: long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854

✍ J.A van der Hage; C.J.H van de Velde; J.-P Julien; J.-L Floiras; T Delozier; C V 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Early Versus Delayed Endocrine Treatment

Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)

✍ Fritz H. Schröder; Karl-Heinz Kurth; Sophie D. Fossa; Wytse Hoekstra; Peter P. K 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 1023 KB

Re: Fritz H. Schröder, Karl-Heinz Kurth,

Re: Fritz H. Schröder, Karl-Heinz Kurth, Sophie D. Fossa, et al. Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial). Eur Urol 2009;55:14–22

✍ Tomasz Drewa 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB